Europe Neoantigens Market Share and Forecast by 2028

Historic Data: 2021-2022   |   Base Year: 2023   |   Forecast Period: 2024-2028

Europe Neoantigens Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Treatment (Combination Therapy and Mono Therapy) and Therapeutic Specialty (Gastrointestinal Cancer, Lung Cancer, Solid Tumor, Urinary Systems Cancers, Melanoma, Head and Neck Cancer, and Others)

  • Report Code : TIPRE00025574
  • Category : Life Sciences
  • No. of Pages : 76
Buy Now

The neoantigens market in Europe is expected to grow from US$ 86,165.00 thousand in 2023 to US$ 341,855.35 thousand by 2028; it is estimated to grow at a CAGR of 31.7% from 2023 to 2028.



The UK, Germany, and France are major economies in Europe. Evolution in neoantigen vaccines against cancer is the major factor driving the growth of the Europe neoantigens market. Developments in biotechnology have led to rise in acceptance for immunotherapy, further driving its use in personalized medicines. Immunotherapy is widely used to treat cancer; a few the immunotherapy procedures involve the use of neoantigens, the antigens present on the surface of cancer cells. Therefore, applications of neoantigens are being widely studied to treat cancer. The uniqueness of neoantigens allows researchers to identify patients’ immune system and find antigens to target cancer cells without disturbing healthy cells. The developments in immunotherapy caught pace after 2015, when the first clinical trial of neoantigen vaccine was performed. In 2017, two additional clinical trial studies were published by Neon Therapeutics that proved the efficacy of neoantigen vaccine treat melanoma (skin cancer) in humans. The positive results of clinical trials have attracted various startups to discover and develop neoantigen-based cancer therapeutics. Many companies have shown interest in the development of neoantigens. Following are few examples of companies involved in the development of neoantigens.

•   BioNTech SE is a German company operating in the neoantigen vaccines market. BioNTech SE has developed Individualized Vaccines Against Cancer (IVAC) Mutanome platform that engineer RNA molecules to produce customized neoantigen vaccine. The clinical trials for IVAC that target triple negative breast cancer, multiple tumor types, and melanoma are pending.

•   The ATLAS platform of Genocea Biosciences uses an ex-vivo method to develop neoantigen vaccines. Genocea Biosciences has raised ~US$ 91 million funds from investors such as Polaris Partners, GlaxoSmithKline, and Johnson & Johnson Innovation to develop its neoantigen cancer vaccine—GEN-009. Currently in the Phase 1a/2 clinical trial, the vaccine is designed to treat melanoma, lung cancer, and carcinomas.

•   Gritstone Oncology uses its AI platform—EDGE—to develop neoantigen vaccines using an in-silico approach. The company has developed two products GRANITE-001 and SLATE-001. GRANITE-001 is designed as an individual treatment based on patient’s specific tumor type, whereas SLATE-001 is formulated as a common neoantigen vaccine that can be used for multiple patients showing similar neoantigen.

•   Agenus Inc. has developed AutoSynVax (ASV) neoantigen vaccine that is administered with an adjuvant QS-21 Stimulon to treat solid tumors. At present ASV is in the Phase 1 clinical trial in USA.

•   Since 2016, Moderna, Inc. is involved in clinical trials for its personalized cancer vaccine (PCV) mRNA-4157 in combination with Keytruda by Merck. In November 2020, Moderna, Inc. published updates about its cancer vaccines stating that administrating mRNA-4157 in combination with Keytruda is well tolerated at all dose levels and has produced responses in patients.

Such developments in the neoantigen vaccines against cancer are fueling the market growth.

In Europe, there is an exponential growth of COVID-19 cases. Spain, Italy, Germany, France, and the UK are among the most affected European countries. As per the Worldometer, as of May 6th, 2020, Spain, the UK, Italy, Germany, and France recorded 3,551,262; 4,425,940; 4,070,400; 3,469,448; and 5,706,378, COVID-19 cases, respectively, and the deaths toll is also high in these countries. As per the news article, due to COVID-19 emergency, access to chemotherapy, scans, transplants, and surgery has become difficult for thousands of cancer patients in Italy. According to the research led by Codice Viola, charity that supports pancreatic cancer patients found that more than 500 breast or pancreatic patients’ appointments for chemotherapy or radiotherapy were postponed. Additionally, 64% of surgical procedures were postponed and more than half of the follow-up appointments rescheduled. Additionally, in Europe, many of the cancer vaccine development companies have been directed to develop COVID-19 vaccine. For instance, on April 2020, NEC announced that, after its neoantigen cancer vaccine project, it is planning to develop COVID-19 vaccine using AI with a close collaboration with NOI, a biotechnology subsidiary located in Oslo, Norway. Also, patient enrollment in clinical trials has been significantly declined. These factors are likely to have negative impact on the market growth.

  • This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Europe Neoantigens Market Segmentation

Europe Neoantigens Market – By Treatment

  • Combination Therapy
  • Mono Therapy

Europe Neoantigens Market – By Therapeutic Specialty

  • Gastrointestinal Cancer
  • Lung Cancer
  • Solid Tumors
  • Urinary System Cancers
  • Melanoma
  • Head and Neck Cancer
  • Others

Europe Neoantigens Market– By Country

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Europe Neoantigens Market-Companies Mentioned

  • Achilles Therapeutics plc
  • Frame Cancer Therapeutics
  • Genocea
  • Immunicum AB
  • Medigene AG
  • Moderna, Inc

Europe Neoantigens Report Scope

Report Attribute Details
Market size in 2023 US$ 86,165.00 thousand
Market Size by 2028 US$ 341,855.35 thousand
Global CAGR (2023 - 2028) 31.7%
Historical Data 2021-2022
Forecast period 2024-2028
Segments Covered By Treatment
  • Combination Therapy and Mono Therapy
By Therapeutic Specialty
  • Gastrointestinal Cancer
  • Lung Cancer
  • Solid Tumor
  • Urinary Systems Cancers
  • Melanoma
  • Head and Neck Cancer
Regions and Countries Covered Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Market leaders and key company profiles
  • Achilles Therapeutics plc
  • Frame Cancer Therapeutics
  • Genocea
  • Immunicum AB
  • Medigene AG
  • Moderna, Inc
    • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
    • PEST and SWOT Analysis
    • Market Size Value / Volume - Global, Regional, Country
    • Industry and Competitive Landscape
    • Excel Dataset
    europe-neoantigens-market-report-deliverables-img1
    europe-neoantigens-market-report-deliverables-img2
    Report Coverage

    Report Coverage

    Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

    Segment Covered

    Segment Covered

    This text is related
    to segments covered.

    Regional Scope

    Regional Scope

    North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

    Country Scope

    Country Scope

    This text is related
    to country scope.

    Trends and growth analysis reports related to Life Sciences : READ MORE..   

    Europe Neoantigens Market
    Connect With Expert
    1. Achilles Therapeutics plc
    2. Frame Cancer Therapeutics
    3. Genocea
    4. Immunicum AB
    5. Medigene AG
    6. Moderna, Inc
    europe-neoantigens-market-cagr